The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: Implications for antiplatelet therapy

Blood

Volumn 117, Issue 3, 2011, Pages 1005-1013

  Stolla, Moritz ^a   Stefanini, Lucia ^a   Roden, R Claire ^a   Chavez, Massiel ^a   Hirsch, Jessica ^b   Greene, Teshell ^b   Ouellette, Timothy D ^a   Maloney, Sean F ^c   Diamond, Scott L ^c   Poncz, Mortimer ^b   Woulfe, Donna S ^a   Bergmeier, Wolfgang ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM; CALCIUM AND DIACYLGLYCEROL REGULATED GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; CLOPIDOGREL; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INTEGRIN; INTEGRIN ALPHA2B BETA 3; PURINERGIC P2Y12 RECEPTOR; RAS PROTEIN; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTERY BLOOD FLOW; ARTICLE; BLEEDING; CONTROLLED STUDY; HEMOSTASIS; KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE ADHESION; THROMBOGENESIS; THROMBOSIS; THROMBUS;

EID: 78751696504     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-297713     Document Type: Article

References (45)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-1234.
2. Alexander JH. The current state of antiplatelet therapy in acute coronary syndromes: the data and the real world. Cleve Clin J Med. 2009;76(suppl 1):S16-23.
3. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9(2):154-169.
4. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112(8):3011-3025.
5. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-687.
6. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238.
7. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106(3):385-392. (Pubitemid 30655638)
8. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther. 2005;108(2):180-192. (Pubitemid 41528788)
9. Andre P. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112(3):398-406. (Pubitemid 38063768)
10. Nergiz-Unal R, Cosemans JM, Feijge MA, et al. Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques. PLoS ONE. 2010;5(4):e10130.
11. Cifuni SM, Wagner DD, Bergmeier W. CalDAGGEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood. 2008;112(5):1696-1703.
12. Stefanini L, Roden RC, Bergmeier W. CalDAGGEFI is at the nexus of calcium-dependent platelet activation. Blood. 2009;114(12):2506-2514.
13. Kawasaki H, Springett GM, Toki S, et al. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci U S A. 1998;95(22):13278-13283. (Pubitemid 28509562)
14. Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004;10(9):982-986. (Pubitemid 39273740)
15. Bergmeier W, Stefanini L. Novel molecules in calcium signaling in platelets. J Thromb Haemost. 2009;7(suppl 1):187-190.
16. Johnson JE, Goulding RE, Ding Z, et al. Differential membrane binding and diacylglycerol recognition by C1 domains of RasGRPs. Biochem J. 2007;406(2):223-236. (Pubitemid 47310953)
17. Konopatskaya O, Gilio K, Harper MT, et al. PK-Calpha regulates platelet granule secretion and thrombus formation in mice. J Clin Invest. 2009; 119(2):399-407.
18. Lian L, Wang Y, Flick M, et al. Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood. 2009;113(15):3577-3584.
19. Quinton TM, Kim S, Dangelmaier C, et al. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonistinduced fibrinogen receptor activation. Biochem J. 2002;368(Pt 2):535-543.
20. Lova P. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets. J Biol Chem. 2002;277(14):12009-12015.
21. Chrzanowska-Wodnicka M. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest. 2005;115(3):680-687. (Pubitemid 40322242)
22. Zou Z, Chen H, Schmaier AA, Hynes RO, Kahn ML. Structure-function analysis reveals discrete beta3 integrin inside-out and outside-in signaling pathways in platelets. Blood. 2007;109(8):3284-3290.
23. Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B. Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry. 2002;48(2):80-86. (Pubitemid 34591919)
24. Neeves KB, Maloney SF, Fong KP, et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost. 2008;6(12):2193-2201.
25. Bergmeier W, Rackebrandt K, Schröder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 2000;95(3):886-893.
26. Neyman M, Gewirtz J, Poncz M. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood. 2008;112(4):1101-1108.
27. Hechler B, Nonne C, Eckly A, et al. Arterial thrombosis: relevance of a model with two levels of severity assessed by histological, ultrastructural and functional characterization. J Thromb Haemost.2010;8(1):173-84.
28. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest. 2007;117(4):953-960.
29. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(4):728-739.
30. Bergmeier W, Goerge T, Wang H-W, et al. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest. 2007;117(6):1699-1707. (Pubitemid 46871354)
31. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol. 2010;159(3):502-517.
32. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122(1):165-171.
33. Fontayne A, Meiring M, Lamprecht S, et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost. 2008;100(4):670-677.
34. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116(23):2678-2686. (Pubitemid 350291240)
35. Lian L, Wang Y, Draznin J, et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood. 2005;106(1):110-117.
36. Bos JL, de Rooij J, Reedquist KA. Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol. 2001;2(5):369-377.
37. Nieswandt B, Moser M, Pleines I, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med. 2007;204(13):3113-3118.
38. Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007;204(13):3103-3111.
39. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fässler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008;14(3):325-330. (Pubitemid 351347914)
40. Crittenden JR, Cantuti-Castelvetri I, Saka E, et al. Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci U S A. 2009;106(8):2892-2896.
41. Clyde-Smith J, Silins G, Gartside M, et al. Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor. J Biol Chem. 2000;275(41):32260-32267.
42. Caloca MJ, Zugaza JL, Bustelo XR. Exchange factors of the RasGRP family mediate Ras activation in the Golgi. J Biol Chem. 2003;278(35):33465-33473.
43. Colón-González F, Kazanietz MG. C1 domains exposed: from diacylglycerol binding to proteinprotein interactions. Biochim Biophys Acta. 2006;1761(8):827-837. (Pubitemid 44404081)
44. Hausser A, Storz P, Link G, et al. Protein kinase C mu is negatively regulated by 14-3-3 signal transduction proteins. J Biol Chem. 1999;274(14):9258-9264.
45. Williams JG, Drugan JK, Yi GS, Clark GJ, Der CJ, Campbell SL. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine- rich domain interactions. J Biol Chem. 2000;275(29):22172-22179.